Mifepristone-misoprostol abortion: A trial in rural and urban Maharashtra, India (HTML)
Coyaji,Kurus; Elul,Batya; Krishna,Usha; Otiv,Suhas; Ambardekar,Shubha; Bopardikar,Arti; Raote,Veena; Ellertson,Charlotte; Winikoff,Beverly
Contraception 66(1): 33-40
Publication date: 2002
As several important policy questions remain regarding the use of medical abortion in developing countries, we investigated the safety, efficacy, and acceptability of mifepristone-misoprostol abortion in the outpatient family planning departments of two urban hospitals and one rural hospital in India. Nine-hundred women (with gestations of =63 days in the urban sites and =56 days in the rural site) received 600 mg mifepristone followed 48 h later by 400 µg oral misoprostol in the clinic. Four point four percent or fewer urban women and 1.0% rural women were lost to follow-up. Perfect and typical-use failure rates were low at all sites. While rural women reported fewer side effects at all sites, the vast majority of women were satisfied with their medical abortions. Medical abortion can be offered safely, effectively, and acceptably in the outpatient family planning departments of urban and rural hospitals in India.
For 60 years, the Population Council has changed the way the world thinks about important health and development issues. Explore an interactive timeline of the Council's history, learn more about some of our key contributions, and watch a short video about why your support is so important to us.